Cite
HARVARD Citation
Sharma, S. et al. (2022). Rituximab, a Safer Option for Rheumatoid Arthritis: A Comparison of the Reported Adverse Events of Approved Monoclonal Antibodies. Journal of pharmacology and pharmacotherapeutics. 13 (4), pp. 330-340. [Online].